This meta-analysis assesses the relationship between vitamin D supplementation and incidence of major adverse cardiovascular events (MACEs). Pubmed, Web of science, Ovid, Cochrane Library and Clinical Trials were used to systematically search from their inception until July 2024. Hazard ratios (HR) and 95% confidence intervals (95%CI) were employed to assess the association between vitamin D supplementation and MACEs. This analysis included 5 randomized controlled trials (RCTs). Pooled results showed no significant difference in the incidence of MACEs (HR: 0.96; p=0.77), expanded MACEs (HR: 0.96; p=0.77) between the vitamin D intervention group and the control group. Further, the vitamin D intervention group had a lower incidence of myocardial infarction (MI), but the difference was not statistically significant (HR: 0.88, 95%CI: 0.77-1.01; p=0.061); nevertheless, vitamin D supplementation had no effect on the reduced incidence of stroke (p=0.675) or cardiovascular death (p=0.422). Among males (p=0.109) and females (p=0.468), vitamin D supplementation had no effect on the reduced incidence of MACEs. For participants with a body mass index (BMI)<25 kg/m2, the difference was not statistically significant (p=0.782); notably, the vitamin D intervention group had a lower incidence of MACEs for those with BMI≥25 kg/m2 (HR: 0.91, 95%CI: 0.83-1.00; p=0.055). Vitamin D supplementation did not significantly contribute to the risk reduction of MACEs, stroke and cardiovascular death in the general population, but may be helpful for MI. Notably, effect of vitamin D supplementation for MACEs was influenced by BMI. Overweight/obese people should be advised to take vitamin D to reduce the incidence of MACEs.